Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2021

View Archived Issues

GeneTACs show promise for treating myotonic dystrophy type 1

Jiangsu Simcere Pharmaceutical R&D patents DNA repair protein RAD51 homolog 1 inhibitors

Sphingomyelin-derived camptothecin nanovesicle platform for improved cancer immunochemotherapy

Unveiling immune-malignant cell hubs underlying cancer immunologic and tumorigenic processes

Engineered macrophages for chemo/photo/immunotherapy of primary and bone metastatic breast cancer

JMJD1C demethylase as novel target for AR-negative prostate cancer

Inflazome patents NLRP3 inflammasome inhibitors

Janssen Pharmaceutica presents Mcl-1 inhibitors

Shanghai Henlius Biotech discloses CD137-targeting antibodies

MASP2 levels are increased in children with severe asthma

Metabolomics study reveals dementia-linked metabolites

PRS-220 shows favorable PK and biodistribution in fibrotic lung models

KIM-1 unveiled as a marker of COVID-19 severity

Combined inhibition of RIPK1 and ferroptosis as potential therapeutic strategy for AKI

ARN-19702 shows broad analgesic effect in animal models of pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...